alexa Pharmacoeconomic Analysis of the Therapies Used in the
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Pharmacoeconomic Analysis of the Therapies Used in the Treatment of Smoking in a Specialized Unit

Pedro J Tarraga Lopez*, Raul Grdoy, Francisco Javier Callejas, Ana I Tornero, Jose Antonio Rodriguez Montes, Angel Molina and Denis Oriot

Health Service of Castilla-La Mancha Albacete, Albacete, Spain

*Corresponding Author:
Pedro J Tarraga Lopez
Health Service of Castilla-La Mancha Albacete
Albacete, Spain
Tel: 34609080627
Fax: 3467225533
E-mail: [email protected]

Received April 24, 2016; Accepted May 13, 2016; Published May 16, 2016

Citation: Lopez PJT, Grdoy R, Callejas FJ, Tornero AI, Montes JAR, et al. (2016) Pharmacoeconomic Analysis of the Therapies Used in the Treatment of Smoking in a Specialized Unit. J Pulm Respir Med 6:347. doi:10.4172/2161-105X.1000347

Copyright: © 2016 Lopez PJT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objective: Cost-effectiveness analysis of the major tobacco control tools medium long term.

Method: This is a retrospective, descriptive study of the results obtained after analyzing the sample of all patients who attended the Unit Specialized Treatment Smoking during two years. Without drug treatment: the costs and effectiveness of the four options used in our Unit for smoking cessation compared: 1) Bupropion+ NRT, 2) Varenicline, 3) Varenicline and NRT and 4) No pharmacology treatment.

Costs and efficiency: Efficiencies rates for comparison are the result of our study for the 4 options. All costs are expressed in euros, both costs and an effect beyond the first year rate of 3.5% per annum is deducted.

Results: Of the 559 patients, 32.7% received no treatment. 34.5% (n=194) of patients was treated with NRT (gum, patches or in combination with varenicline). Varenicline is the second most frequently used drug with 22.9% and, finally, bupropion (9.8%). The analysis results show that the greater efficacy of varenicline is a better cost/effectiveness (C/E) in the treatment of smoking medium to long term that comes to fully offset the higher cost of treatment compared to the other options. So both varenicline monotherapy as associated with TSN have average costs of € 2.491,21 and € 2.432,22 per patient who quit smoking compared to the other options with Bupropion and TSN 4.136,55 € or drug treatment to 5.783,88 € in a perspective of two years.

Conclusion: The option of giving Varenicline is a better cost/effectiveness (C/E) in the treatment of smoking-half longer than the other options.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords